Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
WALTHAM, Mass., May 10, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 24, 2017 from 8:30 a.m. to 12:00 p.m. Eastern Time. Members of AMAG’s management team and industry experts will provide updates on the Company’s pipeline and commercial programs. In-person attendance requires advanced registration. Please email [email protected] for further information.
A live webcast of the event will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will also be available and archived on the site.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
